Show simple item record

dc.contributor.authorAl-mansoori, Layla
dc.contributor.authorElsinga, Philip
dc.contributor.authorGoda, Sayed K.
dc.date.accessioned2022-01-13T09:33:30Z
dc.date.available2022-01-13T09:33:30Z
dc.date.issued2021-10-01
dc.identifier.citationAl-Mansoori, L., Elsinga, P. and Goda, S.K., 2021. Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomedicine & Pharmacotherapy, 144, pp. 1-15.en_US
dc.identifier.issn0753-3322
dc.identifier.doi10.1016/j.biopha.2021.112260
dc.identifier.urihttp://hdl.handle.net/10545/626193
dc.description.abstractAbnormal structural and molecular changes in malignant tissues were thoroughly investigated and utilized to target tumor cells, hence rescuing normal healthy tissues and lowering the unwanted side effects as non-specific cytotoxicity. Various ligands for cancer cell specific markers have been uncovered and inspected for directional delivery of the anti-cancer drug to the tumor site, in addition to diagnostic applications. Over the past few decades research related to the ligand targeted therapy (LTT) increased tremendously aiming to treat various pathologies, mainly cancers with well exclusive markers. Malignant tumors are known to induce elevated levels of a variety of proteins and peptides known as cancer “markers” as certain antigens (e.g., Prostate specific membrane antigen “PSMA”, carcinoembryonic antigen “CEA”), receptors (folate receptor, somatostatin receptor), integrins (Integrin αvβ3) and cluster of differentiation molecules (CD13). The choice of an appropriate marker to be targeted and the design of effective ligand-drug conjugate all has to be carefully selected to generate the required therapeutic effect. Moreover, since some tumors express aberrantly high levels of more than one marker, some approaches investigated targeting cancer cells with more than one ligand (dual or multi targeting). We aim in this review to report an update on the cancer-specific receptors and the vehicles to deliver cytotoxic drugs, including recent advancements on nano delivery systems and their implementation in targeted cancer therapy. We will discuss the advantages and limitations facing this approach and possible solutions to mitigate these obstacles. To achieve the said aim a literature search in electronic data bases (PubMed and others) using keywords “Cancer specific receptors, cancer specific antibody, tumor specific peptide carriers, cancer overexpressed proteins, gold nanotechnology and gold nanoparticles in cancer treatment” was carried out.en_US
dc.description.sponsorshipQatar National Research Funden_US
dc.language.isoenen_US
dc.publisherElsevier BVen_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S0753332221010441#!en_US
dc.rights© 2021 The Author(s). Published by Elsevier Masson SAS.
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://www.elsevier.com/tdm/userlicense/1.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPharmacologyen_US
dc.subjectGeneral Medicineen_US
dc.titleBio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapyen_US
dc.typeArticleen_US
dc.contributor.departmentQatar University, Doha, Qataren_US
dc.contributor.departmentUniversity Medical Center Groningen, the Netherlandsen_US
dc.contributor.departmentCairo University, Egypten_US
dc.contributor.departmentUniversity of Derbyen_US
dc.identifier.journalBiomedicine & Pharmacotherapyen_US
dc.identifier.piiS0753332221010441
dc.source.journaltitleBiomedicine & Pharmacotherapy
dc.source.volume144
dc.source.beginpage112260
dcterms.dateAccepted2021-09-26
dc.author.detailN/Aen_US


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record